- Trial phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Why 4/10
- AB-101 has no hard dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The clinical hold was lifted on October 22, 2026, but the company is still evaluating next steps for clinical development. As an early-stage (Phase 1a/1b) asset at a company with other pipeline programs (imdusiran is more advanced), the impact score defaults to 4.
The next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
Price Chart
Executive Summary
AB-101 is an oral small-molecule PD-L1 inhibitor in Phase 1a/1b clinical development by Arbutus Biopharma Corp (NASDAQ: ABUS) for chronic hepatitis B virus (HBV) infection. On October 22, 2026, the FDA lifted a clinical hold on AB-101's IND, allowing U.S. clinical development to resume. Early data from the AB-101-001 trial presented at AASLD 2025 showed the drug was well tolerated up to 30mg daily for 28 days in chronic HBV patients, with 83% mean maximal PD-L1 receptor occupancy at the 30mg dose. The company is still evaluating next steps for the program. AB-101 is one of two key HBV assets at Arbutus, alongside the more advanced RNAi therapeutic imdusiran (Phase 2a). The stock trades at $3.72 near its 52-week low, with a market cap supported by a recent $178M Moderna patent settlement and $230M share buyback.
How It Works
AB-101 is an oral (pill) small molecule that blocks the PD-L1 protein. PD-L1 is a 'brake' that cancer cells and virus-infected cells use to hide from the immune system. By blocking PD-L1, AB-101 releases this brake, allowing the body's T-cells to recognize and attack liver cells infected with hepatitis B virus. Unlike injected PD-1/PD-L1 inhibitors used in cancer, AB-101 is taken by mouth, which could make it more convenient for chronic hepatitis B patients who need long-term treatment.
Trial Status
AB-101 is being studied in the Phase 1a/1b AB-101-001 trial. Part 3 data in chronic HBV patients showed once-daily 10mg dosing for 28 days was well tolerated with PD-L1 receptor occupancy similar to healthy volunteers. Data presented at AASLD 2025 showed doses up to 30mg QD for 28 days were generally well tolerated, with 83% mean maximal PD-L1 receptor occupancy at 30mg. The FDA clinical hold was lifted on October 22, 2026, and the company is evaluating next steps for clinical development.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings call on November 11, 2026, which may include updates on AB-101's clinical development plans
- Announcement of next clinical trial design and timeline for AB-101 now that the FDA hold is lifted
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arbutus Biopharma Corporation PRESS-RELEASE ABUS ·Originating report